Federal health officials on Thursday recommended revoking approval of the drug Avastin to fight breast cancer, citing the medication's poor performance in follow-up studies and its potential for serious side effects.
 All Content by Mehr News Agency is licensed under a Creative Commons Attribution 4.0 International License.